Quarterly report · Q3
4272.TEDINET S100Q44W
Period2022-04-01 → 2022-12-31
Filed2023-02-08
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥153.6bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥184.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥138.1bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥19.1bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥17.3bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥21.0bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.8bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥21.6bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥19.9bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥15.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥15.3bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥14.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥331.4bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥315.5bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥309.6bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥75.7bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥69.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥255.7bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥246.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥238.0bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥41.5bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥38.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥90.62 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.57 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.1 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.85 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥90.6 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥101.65 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥83.09 | 2021-04-01 → 2021-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 76.9% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.6% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 52
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-12-31 | ¥8.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥7.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥82m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-12-31 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥204m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥204m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥5.7bn |
| jpcrp040300-q3r_E00836-000Functional Chemicalsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥65.6bn |
| jpcrp040300-q3r_E00836-000Functional Chemicalsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥65.4bn |
| jpcrp040300-q3r_E00836-000Functional Chemicalsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥122m |
| jpcrp040300-q3r_E00836-000Functional Chemicalsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥10.1bn |
| jpcrp040300-q3r_E00836-000Medicinereportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥39.3bn |
| jpcrp040300-q3r_E00836-000Medicinereportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥39.3bn |
| jpcrp040300-q3r_E00836-000Medicinereportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E00836-000Medicinereportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥6.9bn |
| jpcrp040300-q3r_E00836-000Safety Systemsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥41.0bn |
| jpcrp040300-q3r_E00836-000Safety Systemsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥41.0bn |
| jpcrp040300-q3r_E00836-000Safety Systemsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥6.2bn |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥145.8bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥145.7bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥122m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥23.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥153.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥153.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥204m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥24.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-12-31 | ¥6.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-12-31 | ¥6.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥78m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-12-31 | ¥1.4bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥184m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥184m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥5.2bn |
| jpcrp040300-q3r_E00836-000Functional Chemicalsreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥58.7bn |
| jpcrp040300-q3r_E00836-000Functional Chemicalsreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥58.5bn |
| jpcrp040300-q3r_E00836-000Functional Chemicalsreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥106m |
| jpcrp040300-q3r_E00836-000Functional Chemicalsreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥9.5bn |
| jpcrp040300-q3r_E00836-000Medicinereportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥39.7bn |
| jpcrp040300-q3r_E00836-000Medicinereportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥39.7bn |
| jpcrp040300-q3r_E00836-000Medicinereportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥0 |
| jpcrp040300-q3r_E00836-000Medicinereportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥6.9bn |
| jpcrp040300-q3r_E00836-000Safety Systemsreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥33.3bn |
| jpcrp040300-q3r_E00836-000Safety Systemsreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥33.3bn |
| jpcrp040300-q3r_E00836-000Safety Systemsreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥4.7bn |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥131.7bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥131.6bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥106m |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥21.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-12-31 | ¥138.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-12-31 | ¥138.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥184m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-12-31 | ¥22.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 399
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E00836-000MedicineReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E00836-000SafetySystemsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 106000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 78000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 184000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -184000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00836-000FunctionalChemicalsReportableSegmentsMember | 58651000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00836-000MedicineReportableSegmentsMember | 39746000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00836-000SafetySystemsReportableSegmentsMember | 33272000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 131670000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 6610000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 138280000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -184000000 | JPY |
| Net sales | Prior1YTDDuration | 138095000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00836-000FunctionalChemicalsReportableSegmentsMember | 9539000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00836-000MedicineReportableSegmentsMember | 6898000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00836-000SafetySystemsReportableSegmentsMember | 4718000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 21156000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1414000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 22571000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -5231000000 | JPY |
| Operating income | Prior1YTDDuration | 17339000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00836-000FunctionalChemicalsReportableSegmentsMember | 65433000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00836-000MedicineReportableSegmentsMember | 39293000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00836-000SafetySystemsReportableSegmentsMember | 40951000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 145678000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 7949000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 153627000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 153627000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00836-000FunctionalChemicalsReportableSegmentsMember | 122000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00836-000MedicineReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00836-000SafetySystemsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 122000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 82000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 204000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -204000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00836-000FunctionalChemicalsReportableSegmentsMember | 65555000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00836-000MedicineReportableSegmentsMember | 39293000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00836-000SafetySystemsReportableSegmentsMember | 40951000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 145800000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 8032000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 153832000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -204000000 | JPY |
| Net sales | CurrentYTDDuration | 153627000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00836-000FunctionalChemicalsReportableSegmentsMember | 10067000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00836-000MedicineReportableSegmentsMember | 6944000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00836-000SafetySystemsReportableSegmentsMember | 6165000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |